RSF1 and not cyclin D1 gene amplification may predict lack of benefit from adjuvant tamoxifen in high-risk pre-menopausal women in the MA.12 randomized clinical trial.

av Dana Keilty, Marguerite Buchanan, Katerina Ntapolias, Olga Aleynikova, Dongsheng Tu, Xiao Li, Lois Shepherd, Vivien Bramwell, Mark Basik
Publicerad 2013-01-01